10 Years of SGLT2 Inhibitors: A Decade of Redefining Cardiometabolic Care

This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.

Related Keywords

United States ,American ,Eli Lilly ,Steve Nissen ,Steve Greene ,Kathy Wolski ,Jane Davis ,Natalie Bellini ,Diana Isaacs ,Kim Zuber ,Drug Administration ,University Of Alabama At Birmingham ,European Society Of Cardiology Congress ,American Academy Of Nephrology Physician Assistants ,Lab Us Published ,A Silver Lining For Cardiometabolic Health ,Diabetes Technology Program At University Hospitals ,Diabetes Work Group ,York Heart Association ,Duke Clinical Research Institute ,Johnson ,Metabolic Care Center ,Collaborative Group ,Astrazeneca ,Diabetes Technology Program ,University Hospitals Diabetes ,Silver Lining ,New England Journal ,New York Heart Association ,European Society ,Cardiology Congress ,Triple Crown ,American Academy ,Nephrology Physician Assistants ,Diabetes Dialogue ,Real World Perspectives ,May Predispose ,Heart Failure ,American College ,American Heart Association Joint Committee ,Clinical Practice Guidelines ,Improving Global Outcomes ,Diabetes Work ,Practice Guideline ,Diabetes Management ,Chronic Kidney ,Diabetes Mellitus Evaluating Cardiovascular Risk ,New Antidiabetic Therapies ,Treat Type ,Federal Register ,Published December ,Published August ,Cardiovascular Outcomes ,Renal Events ,Reduced Ejection ,Preserved Ejection ,Renal Outcomes ,